Human Genome (HGSI) straddles expensive into Phase Three data
Down)
Human Genome (Nasdaq: HGSI) : Human Genome closed at $2.92. HGSI is expected to report top-line Phase three BLISS-56 data on LymphoStat-B this summer. HGSI July 2.5 straddle is priced at 80c, August 2.5 straddle is priced at $1.85, October 2.5 straddle is priced at $2.20 according to Track Data, suggesting large price movement. Paul Foster
You May Also Be Interested In
- Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) Downgraded
- Siliconware Precision (SPIL) Shares Drop on Volatility Spike
- Corinthian Colleges (COCO) Bounces Off Intraday Lows into Close
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
